Mylan Company Profile (NASDAQ:MYL)

About Mylan (NASDAQ:MYL)

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:MYL
  • CUSIP: 62853010
  • Web:
  • Market Cap: $21 billion
  • Outstanding Shares: 535,950,000
Average Prices:
  • 50 Day Moving Avg: $38.09
  • 200 Day Moving Avg: $38.84
  • 52 Week Range: $33.60 - $50.40
  • Trailing P/E Ratio: 39.14
  • Foreward P/E Ratio: 6.91
  • P/E Growth: 0.88
Sales & Book Value:
  • Annual Revenue: $11.61 billion
  • Price / Sales: 1.81
  • Book Value: $21.75 per share
  • Price / Book: 1.80
  • EBIDTA: $3.8 billion
  • Net Margins: 2.50%
  • Return on Equity: 22.04%
  • Return on Assets: 8.43%
  • Debt-to-Equity Ratio: 1.10%
  • Current Ratio: 0.83%
  • Quick Ratio: 0.55%
  • Average Volume: 5.81 million shs.
  • Beta: 1.14
  • Short Ratio: 3.67

Frequently Asked Questions for Mylan (NASDAQ:MYL)

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) announced its earnings results on Wednesday, May, 10th. The company reported $0.93 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.92 by $0.01. The company earned $2.72 billion during the quarter, compared to analyst estimates of $2.81 billion. Mylan had a return on equity of 22.04% and a net margin of 2.50%. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the company posted $0.76 earnings per share. View Mylan's Earnings History.

What guidance has Mylan issued on next quarter's earnings?

Mylan updated its FY17 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of $5.15-5.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.35. The company issued revenue guidance of +17% to $12.25-13.75 billion, compared to the consensus revenue estimate of $12.64 billion.

Where is Mylan's stock going? Where will Mylan's stock price be in 2017?

20 brokerages have issued 1 year target prices for Mylan's shares. Their forecasts range from $40.00 to $70.00. On average, they anticipate Mylan's share price to reach $51.88 in the next year. View Analyst Ratings for Mylan.

What are analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:

  • 1. According to Zacks Investment Research, "Mylan’s first-quarter results beat on earnings but missed the top line due to decline in EpiPen sales as a result of increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year. In addition, the company recent suffered a few setbacks. Mylan received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus. In Apr 2017, Mylan received a warning letter from the FDA for its manufacturing facility in India. The FDA cited significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals in the warning letter. The violations relate to the agency’s inspection in Sep 2016 and even though the company had responded to the same, the agency deemed them inadequate. Nevertheless, shares of Mylan have outperformed the industry in the last six months." (5/15/2017)
  • 2. Mizuho analysts commented, "We were previously modeling 2017 generic Advair sales of $150M ramping to peak sales of $363M in 2020. Without the 2017 contribution we would still fall generally in line with consensus revenue estimates for 2017 (~$12.7B), which is below the mid-point of the guidance range of $12.25-13.75B. It is unclear if Mylan can get its product to the market before year end so it may be more conservative to exclude it for now, though we continue to anticipate its launch next year. While the limited visibility provided on this product may be frustrating to investors, we think that the magnitude of the stock reaction creates a buying opportunity given the small overall contribution from this generic in the near-term. We therefore reiterate our Buy rating and $53 PT. Next Advair-related event: Hikma/Vectura has a May 10 GDUFA date for their own generic Advair, and Hikma indicated that it will be ready to launch immediately after approval. Unlike Mylan’s product, which is hoped to be an AB-rated generic, but also one with brand recognition, Hikma’s generic will not be marketed under a brand name. Hikma mgmt has indicated that its Advair generic will make up the majority of its $120M new-launch guidance in 2017 (assuming one other competitor in the market)." (3/30/2017)
  • 3. Royal Bank of Canada analysts commented, "MYL reported 4Q today and hosted what we thought was an upbeat 2017 Investor Day showcasing an impressive pipeline. While overall performance remains stable avoiding headwinds felt by smaller peers, 2017 EPS and stock upside will be linked to a few key approvals along with business development. No change to Sector Perform rating but our price target moves up to $48 on higher EPS...First time 2017 guidance was favorable but there are a lot of moving parts to consider. We said going in that an ambitious 2017 outlook wouldn't be enough unless it came with a solid 4Q result. While visibility into specific 4Q drivers was not as high as we would like, it did provide some comfort around MYL's overall stability in a challenging generic environment. The 2017 guidance range of $5.15 to $5.55 captured consensus and helped drive the +7% move in the stock today, but focus will now shift to several important drivers to get there. As we suspected, that range includes risk-adjusted generic Advair, generic Copaxone 20/40mg as well as some incremental business development. Epipen profit impact was quantified and the driver of the slight gross margin moderation. Our new forecasts for 2017-19E move higher and are now $5.30, $5.75 and $6.12 (the $6.00 MYL EPS target in 2018E remains). Based on our new 2018 EBITDA, MYL trades at 9.1x EV/EBITDA - above historical pre-2014 levels." (3/2/2017)

Are investors shorting Mylan?

Mylan saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 17,975,806 shares, an increase of 8.3% from the April 13th total of 16,590,546 shares. Based on an average daily trading volume, of 4,284,257 shares, the short-interest ratio is presently 4.2 days. Approximately 3.6% of the shares of the company are short sold.

Who are some of Mylan's key competitors?

Who owns Mylan stock?

Mylan's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (8.66%), BlackRock Inc. (7.25%), Vanguard Group Inc. (5.48%), State Street Corp (3.77%), Pzena Investment Management LLC (1.36%) and FIL Ltd (0.92%). Company insiders that own Mylan stock include Heather M Bresch, John D Sheehan, Joseph C Md Maroon, Laboratories Abbott, Mark W Parrish, Melina E Higgins, Robert J Cindrich, Robert J Coury and Wendy Cameron. View Institutional Ownership Trends for Mylan.

Who sold Mylan stock? Who is selling Mylan stock?

Mylan's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, FMR LLC, State Treasurer State of Michigan, Credit Agricole S A, AQR Capital Management LLC, Teacher Retirement System of Texas, Parametric Portfolio Associates LLC and Wells Fargo & Company MN. Company insiders that have sold Mylan stock in the last year include Heather M Bresch and Laboratories Abbott. View Insider Buying and Selling for Mylan.

Who bought Mylan stock? Who is buying Mylan stock?

Mylan's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Pzena Investment Management LLC, TIAA CREF Investment Management LLC, Morgan Stanley, Wellington Management Group LLP, Teachers Advisors LLC, Vanguard Group Inc. and Menora Mivtachim Holdings LTD.. Company insiders that have bought Mylan stock in the last two years include Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich and Wendy Cameron. View Insider Buying and Selling for Mylan.

How do I buy Mylan stock?

Shares of Mylan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mylan stock cost?

One share of Mylan stock can currently be purchased for approximately $39.18.

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 7 Hold Ratings, 11 Buy Ratings, 2 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $51.88 (32.42% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Barclays PLCUpgradeEqual Weight -> Overweight$47.00 -> $50.00LowView Rating Details
5/21/2017Cowen and CompanyReiterated RatingMarket Perform$55.00 -> $43.00MediumView Rating Details
5/13/2017Royal Bank of CanadaSet Price TargetHold$41.00LowView Rating Details
5/1/2017BMO Capital MarketsInitiated CoverageOutperform$50.00LowView Rating Details
4/18/2017Deutsche Bank AGLower Price TargetBuy$52.00 -> $51.00LowView Rating Details
4/14/2017Wells Fargo & CoReiterated RatingMarket Perform$40.00N/AView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
3/30/2017MizuhoReiterated RatingBuy$53.00LowView Rating Details
3/3/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
1/5/2017Citigroup IncDowngradeBuy -> Neutral$59.00 -> $44.00N/AView Rating Details
1/3/2017BTIG ResearchReiterated RatingBuy$55.00N/AView Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveN/AView Rating Details
10/10/2016JPMorgan Chase & Co.Set Price TargetBuy$52.00N/AView Rating Details
10/10/2016Raymond James Financial, Inc.UpgradeMarket Perform -> Strong-Buy$57.00N/AView Rating Details
9/22/2016ArgusSet Price TargetBuy$55.00N/AView Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/AView Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00N/AView Rating Details
8/25/2016Goldman Sachs Group IncReiterated RatingConviction-Buy$60.00N/AView Rating Details
8/24/2016Bank of America CorpReiterated RatingBuy$70.00N/AView Rating Details
7/12/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00N/AView Rating Details
8/12/2015Susquehanna Bancshares IncLower Price TargetPositive$85.00 -> $68.00N/AView Rating Details
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Mylan (NASDAQ:MYL)
Earnings by Quarter for Mylan (NASDAQ:MYL)
Earnings History by Quarter for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 17$0.92$0.93$2.81 billion$2.72 billionViewN/AView Earnings Details
3/1/2017Q4 2016$1.42$1.57$3.18 billion$3.27 billionViewN/AView Earnings Details
11/9/2016Q3 2016$1.50$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.70$0.70$2.22 billion$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.70$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.63$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mylan (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $5.17 EPS
Next Year EPS Consensus Estimate: $5.67 EPS


Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mylan (NASDAQ:MYL)
Insider Ownership Percentage: 0.71%
Institutional Ownership Percentage: 60.89%
Insider Trades by Quarter for Mylan (NASDAQ:MYL)
Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)
Insider Trades by Quarter for Mylan (NASDAQ:MYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/23/2017Laboratories AbbottMajor ShareholderSell44,000,000$41.60$1,830,400,000.00View SEC Filing  
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mylan (NASDAQ:MYL)
Latest Headlines for Mylan (NASDAQ:MYL)
DateHeadline logoTheravance/Mylan Presents Phase III Data on COPD Candidate - May 24 at 6:50 PM logoTheravance Biopharma and Mylan Report Additional Phase 3 Data ... - PR Newswire (press release) - May 24 at 10:33 AM logoBRIEF-Mylan NV says CEO's 2016 compensation was $13.8 mln - Reuters - May 24 at 10:33 AM logoIt's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date - Benzinga - May 24 at 10:33 AM logoMylan NV breached its 50 day moving average in a Bullish Manner : MYL-US : May 24, 2017 - May 24 at 10:33 AM logo10 highest-paid female CEOs - May 24 at 6:48 AM logoTheravance and Mylan's COPD candidate revefenacin successful in late-stage studies - May 23 at 6:14 PM logoTheravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS - May 23 at 10:20 AM logoBiotech Forum Daily Digest: Analysts Warming To Mylan; Spotlight On Seres Therapeutics - May 22 at 6:00 PM logoMylan Stock Gains Following Barclays Upgrade - May 22 at 6:00 PM logoIt's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date - May 22 at 6:00 PM logoBarclays PLC Upgrades Mylan (MYL) to Overweight - May 22 at 4:28 PM logoMylan (MYL) Rating Reiterated by Cowen and Company - May 21 at 9:28 AM logoValeant: Et Tu Mylan? - May 19 at 7:13 PM logoTheravance Biopharma and Mylan to Present Additional Data for ... - PR Newswire (press release) - May 19 at 11:21 AM logoMylan (MYL) PT Lowered to $43 at Cowen; 'Core Business is Not Growing' - - May 19 at 11:21 AM logoTheravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at ... - PR Newswire (press release) - May 17 at 9:00 AM logoTheravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS - May 17 at 9:00 AM logoMylan N.V. -- Moody's assigns Baa3 to Mylan's euro notes offering; stable outlook - May 17 at 9:00 AM logoMylan to Present at UBS Global Healthcare Conference - May 16 at 11:33 PM logoMylan Honors National Women's Health Week to Empower Women to Take Control of Their Health - PR Newswire (press release) - May 16 at 6:28 PM logo3 Top Healthcare Stocks to Buy Now - May 16 at 10:20 AM logoMylan Honors National Women's Health Week to Empower Women to Take Control of Their Health - May 16 at 10:20 AM logoMylan (MYL) Lowered to Sell at Zacks Investment Research - May 15 at 11:04 AM logoWhy prescription drug prices keep going up - May 14 at 10:34 AM logoHealth: EpiPen maker accused of overcharging for asthma drug - May 12 at 7:21 PM logoTepper's Appaloosa Trims Bets on Pharmaceuticals - May 12 at 7:21 PM logoMylan (MYL) Short Interest Up 8.3% in April - May 12 at 7:04 AM logoMylan (MYL) Earns Buy Rating from Goldman Sachs Group Inc - May 11 at 7:16 PM logoEdited Transcript of MYL earnings conference call or presentation 10-May-17 2:00pm GMT - May 11 at 7:13 PM logoMylan's (MYL) "Sector Perform" Rating Reiterated at Royal Bank of Canada - May 11 at 5:58 PM logoMylan Target of Unusually Large Options Trading (MYL) - May 11 at 10:22 AM logoValeant and Mylan perk up after Teva earnings beat - May 11 at 8:30 AM logoBRIEF-Mylan says EpiPen sales suffer from increased competition - Reuters - May 11 at 8:16 AM logoMylan N.V. Reports 29% Gain In Q1 Profit - - Nasdaq - May 11 at 8:16 AM logoMylan edges past profit estimates - Reuters - May 11 at 8:16 AM logoMylan EpiPen - CNBC - May 11 at 8:16 AM logoMylan (MYL) Beats on Q1 Earnings, Revenues Miss Estimates - May 10 at 6:48 PM logoEpiPen price hike was ‘intentional’: AllergyKids Founder - May 10 at 6:48 PM logoMylan (MYL) Issues Earnings Results, Beats Estimates By $0.01 EPS - May 10 at 3:32 PM logoMylan Reports First Quarter 2017 Results - May 10 at 12:12 PM logoHikma Shares Slide Amid Speculation of FDA Ruling on Generic Advair - May 10 at 12:12 PM logoI'm Losing Money on Mylan, but I'm Not Selling - May 10 at 12:12 PM logoMylan 1Q profit surges on acquisitions, tops forecasts - May 10 at 12:12 PM logoMylan Q1 Revenue Falls Short Of Views As EpiPen Sales Decline - May 10 at 12:12 PM logoMylan edges past profit estimates, backs 2017 forecast - May 10 at 12:11 PM logoMylan’s EpiPen sales have taken a hit - May 10 at 12:11 PM logoMylan Unhappy With FDA Standards for Asthma Drug - May 10 at 12:11 PM logoI'm Losing Money on Mylan, but I'm Not Selling - May 10 at 10:48 AM logoAcquisitions Drive Mylan N.V. Revenue and Earnings Higher in Q1 - May 10 at 10:48 AM



Mylan (MYL) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff